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Cefotiam is a second-generation cephalosporin for parenteral use, and the 
active moiety of a recently developed ester of cefotiam for oral administration, 
cefotiam hexetil. In vitro, cefotiam hexetil is partially hydrolysed to the inac- 
tive d3-isomer of cefotiam (Fig. 1) [ 11, and to a minor extent d3-cefotiam has 
also been detected in serum [ 2,3]. This paper describes a high-performance 
liquid chromatographic (HPLC) assay for the simultaneous determination of 
cefotiam and d3-cefotiam in biological fluids. HPLC methods for the deter- 
mination of the parent drug have already been published [4-71. The method 
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Fig. 1. Structures of cefotiam, its d3-isomer and cefotiam hexetil. 
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was used for analysing serum and blister fluid of healthy volunteers following 
intravenous injection of 200 mg of cefotiam or oral administration of 400 mg 
of cefotiam as cefotiam hexetil. 
EXPERIMENTAL 
Chemicals and reagents 
Cefotiam dihydrochloride (Lot. No. 8 B 2907, activity 835.1 pug/g) and d3- 
cefotiam (Lot. No. M378-R0103, purity 99.0% ) were gifts from Takeda Pharma 
(Stolberg, F.R.G. ). Acetonitrile, HPLC-reagent grade, was obtained from Baker 
Chemicals (Gross-Gerau, F.R.G. ); all other chemicals (analytical grade) were 
from E. Merck (Darmstadt, F.R.G. ). Water was purified through a Mini-Q 
water purification system purchased from Millipore (Eschborn, F.R.G. ) _ 
Stock solutions (lOO~g/ml) were prepared by weighing 11.97 mg of cefotiam 
dihydrochloride in a loo-ml volumetric flask and dissolving in water, and 10.10 
mg of d3-cefotiam in 25 mMsodium phosphate (pH 7.0)) respectively. Aliquots 
of 0.4 ml were stored at - 20’ C, used once and discarded. Further dilution for 
standard and control samples was done in serum or 25 m&f sodium phosphate 
(pH 7.0). 
Apparatus 
The chromatographic system consisted of a Model M 6000A pump, a WISP 
710B autosampler, a TCM column oven (set to 30” C), a Model M 720 system 
controller (all from Millipore Waters Chromatography, Eschborn, F.R.G. ), a 
2141 variable-wavelength monitor (set to 254 nm, Pharmacia, Freiburg, 
F.R.G. ), and a C-R4A integrator (Shimadzu, Duisburg, F.R.G. ) . Initially, a 
LiChrocart@ column (125 mmX4 mm I.D.) filled with LiChrospher@ RP-18, 
5 pm particle size (E. Merck) was used for separation, but higher selectivity 
and performance were achieved with a Hyperchrome@ column (125 mm x 4.6 
mm I.D. ) filled with Spherisorb ODS-2,5 pm particle size (Bischoff, Leonberg, 
F.R.G. ). The mobile phase was prepared by combining 1000 ml of water, 80 ml 
of acetonitrile (100 ml when LiChrospher was used) and 2 ml of acetic acid, 
and adjusted to pH 5.1 with 10 &f sodium hydroxide. The eluent was degassed 
and filtered through a Millipore filter (Type FH 0.45 pm). At a flow-rate of 
1.0 ml/min (back-pressure 5-6 MPa) the retention times for cefotiam and the 
d3-isomer were 4.8-5.4 and 4.3-4.7 min, respectively (Fig. 2). 
Treatment of serum and blister fluid samples 
Sample preparation was performed according to an already published pro- 
cedure [ 81. Because of the lability of p-lactam antibiotics in serum [ 91, all 
frozen specimens were thawed in iced water. In brief, 200 ~1 of serum or blister 
fluid were buffered with 200 ,ul of 50 mA4 sodium phosphate (pH 6.2) and 
deproteinized with 400 ~1 of acetonitrile. The acetonitrile and the lipids were 
486 
A2 
Blrnk 
swum 
A3 
2.0 h 
*rum 
% 
Bl .c 
37.5 q 
dJ-Cl’B 
B3 
Fig. 2. Chromatograms of serum and suction blister fluid (SBF) of a healthy volunteer before and 
after oral admimstration of 400 mg of cefotiam as cefotiam hexetil. Chromatographic conditions 
as described in Experimental. Stationary phase: (A) LiChrospher, eluent containing 10% aceto- 
nitrile; (B) Spherisorb, eluent containing 8% acetonitrile. Samples: Al, aqueous solution of 25 ng 
of cefotiam (CTM, 4.766 min) and 25 ng of d3-cefotiam (d3-CTM, 4.373 min); A2, blank serum; 
A3, serum of the subject 2 h after dosing (concentration 0.062 &ml d3-CTM, 2.35 ,ug/ml CTM); 
Bl, aqueous solution of 37.5 ng of CTM (5.393 min) and 37.5 ng of d3-CTM (4.674 min); B2 and 
B3, suction blister fluids of the same subject 0.5 h (B2,0.202 ,cLg/ml CTM) and 2 h (B3,1.32 ,ug/ 
ml CTM, 0.099 ,ug/ml d3-CTM) after dosing. 
then removed by extraction with 2 ml dichloromethane. After centrifugation, 
up to 50 411 of the aqueous supernate were injected onto the HPLC column. 
Samples were kept in a refrigerator prior to analysis, because the analytes are 
unstable at room temperature (10% decay within 6 h in the autosampler at 25 
27°C). 
Calibration and quality control 
For calibration, three serum samples spiked with 5 or 2 pg/ml cefotiam were 
assayed with each run. For assessing assay variability and accuracy, control 
samples spiked with 10, 5, 1 and 0.2 yg/ml cefotiam were prepared and ana- 
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lysed with each run. For the blister fluid assay the calibration and control 
samples were prepared in 25 mA4 sodium phosphate (pH 7.0, concentrations 2 
pg/ml for standards and 0.5 and 0.1 ,ug/ml for controls). As the recovery, sta- 
bility and detector response of d3-cefotiam were equal to those for cefotiam, 
the same analytical characteristics were assumed for both compounds. 
RESULTS AND DISCUSSION 
As with other p-lactam antibiotics [9], the recovery at concentrations of 5 
and 2 pg/ml was quantitative for cefotiam (serum: 104.9 -+ 3.1%, n = 7; buffer: 
98.8? 3.0%, n=5) and also for d3-cefotiam (serum: 103-107%, n=3; buffer: 
99.2-102%, n=3). Linearity was checked by analysing three standard sets of 
10, 5, 2, 1, 0.5, 0.2 and 0.1 pug/ml cefotiam in serum and water, using a linear 
regression weighing factor of l/x. The coefficients of correlation were better 
than 0.99990. The results obtained from spiked control samples were used for 
assessing precision and accuracy, and are summarized in Table I. The assay 
variability was less than 7% in the concentration range lo-O.2 ,ug/ml. The limit 
of quantitation (determined by replicate analysis of serum dilutions of 100,50 
and 20 ng/ml) was 50 ng/ml (found, 56.4 + 1.6 ng/ml, n= 4). The limit of 
detection (defined as the smallest peak height that was three times the base- 
line noise level) was 10 ng/ml in buffer and blister fluid and 20 ng/ml in serum. 
Chromatograms of serum and blister fluid of a subject receiving 400 mg cefo- 
tiam orally as hexetil are shown in Fig. 2. 
The described reversed-phase HPLC assay for cefotiam and its d3-isomer 
TABLE I 
INTER-ASSAY VARIATION AND ACCURACY FOR CEFOTIAM DETERMINATION IN 
SERUM AND BUFFER OBTAINED FROM SPIKED CONTROL SAMPLES ASSAYED ON 
SUCCESSIVE DAYS 
Number of 
assays 
Concentration Concentration found Coefficient of Accuracy 
added (mean+S.D.) variation (mean k SD.) 
@g/ml 1 be/ml 1 (%) (So) 
Serum 
4 
4 
4 
6 
10.0 10.038 f 0.313 3.1 2.5 k 1.3 
5.0 4.851 k 0.284 5.9 3.4 + 5.4 
10 0.988 k 0.010 1.0 1.2kl.O 
0.2 0.200~0.012 6.1 4.9k2.9 
Buffer’ 
5 
5 
0.5 0.498 f 0.019 3.7 2.8k2.1 
0.1 0.097 f 0.006 6.5 6.1 k 2.7 
“25 mM phosphate buffer (pH 7.0). 
3,981 
2.512 
1,666 
1,000 
0.631 
0,396 
0,231 
0,156 
0,100 
0.063 
0 2 4 6 
time (h) 
Fig. 3. Concentration-time course of cefotiam in serum ( 0 ) , d3-cefotiam in serum (A ) , cefotiam 
in suction blister fluid (w ) and d3-cefotiam in suction blister fluid (A ) of a healthy volunteer 
following oral administration of 400 mg of cefotiam as cefotiam hexetil. 
provides sensitive and reliable determinations in biological fluids. It is based 
on a published sample treatment procedure (refs. 8-10 and references cited 
herein) which is well studied for polar, hydrophilic substances. The pH of mo- 
bile phase had strong influence on the separation of cefotiam and d3-cefotiam 
from endogenous substances; therefore the pH had to be adjusted accurately 
for each run and varied between 5.1 and 5.2. Unfortunately, because of late- 
eluting peaks, the run time had to be set to 15 min although the retention time 
of cefotiam was 5-6 min. This could be prevented by using an ion-pair chro- 
matographic method with tetrabutylammonium salt on a LiChrocart column 
(125 mm x 4 mm I.D.) filled with LiChrospher RP-18 (5 pm particle size) and 
an eluent of 1000 ml of water, 80 ml of acetonitrile, 200 mg of tetrabutylam- 
monium hydrogensulphate and 600 ~1 of acetic acid, pH adjusted to 4.75 with 
10 M sodium hydroxide. In this case, however, separation of cefotiam from its 
d3-isomer was not achieved because of identical retention times (5.4 min at a 
flow-rate of 1.0 ml/min). 
The method was used for the determination of cefotiam and d3-cefotiam in 
serum and blister fluid of six volunteers after intravenous injection of 200 mg 
of cefotiam and oral administration of 400 mg of cefotiam as hexetil [ 111. Only 
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in some of the specimens were low concentrations (up to 0.1 B/ml) of d3- 
cefotiam detected. In one subject, the determination of the d3-isomer was not 
possible because of an interfering peak, whereas no interferences were found 
in the case of cefotiam itself. The concentration-time course of cefotiam and 
of d3cefotiam in serum and suction blister fluid of a volunteer following oral 
administration of 400 mg cefotiam as hexetil is shown in Fig. 3. After intra- 
venous injection of 200 mg of cefotiam, the concentrations of d3-cefotiam were 
at the detection limit or not found at all. Therefore, isomerization of cefotiam 
hexetil may occur at the absorption site [ 1,121. 
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